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Abstract
Immunotherapy holds great promise for treatment of infectious and
malignant diseases and might help to prevent the occurrence and
recurrence of cancer. We produced a plant-derived tumor-associated
colorectal cancer antigen EpCAM (pGA733) at high yields using two
modern plant expression systems. The full antigenic domain of EpCAM
was efficiently purified to confirm its antigenic and immunogenic
properties as compared to those of the antigen expressed in the
baculovirus system (bGA733). Recombinant plant-derived antigen
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induced a humoral immune response in BALB/c mice. Sera from those
mice efficiently inhibited the growth of SW948 colorectal carcinoma cells
xenografted in nude mice, as compared to the EpCAM-specific mAb CO171A. Our results support the feasibility of producing anti-cancer
recombinant vaccines using plant expression systems.
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Abbreviations
TAA

Tumor-associated antigen

EpCAM/GA733

Colorectal cancer-associated antigen

bGA733

Baculovirus-derived GA733-2

pGA733

Plant-derived GA733-2

mAb

Monoclonal antibodies

Introduction
The concept of cancer vaccination as a preventive measure is of
increasing interest to oncology in view of advances in modern molecular
biology and biotechnology [7, 14, 15]. Several anti-cancer vaccines for
the treatment of minimal residual disease are currently in human clinical

trials [6, 21]. The T- and B-cell immune responses against tumorassociated antigens (TAA) could lead to efficient elimination of tumor cells
without harming the surrounding normal tissue, as well as help to
generate long-lasting immunological memory against tumor recurrences,
as already shown in humans and animals [8]. There is also strong
evidence supporting the use of recombinant antigen vaccines, either
alone, or in combination with hormonal, chemotherapeutic and
monoclonal antibody approaches, to treat colorectal cancer [1, 5, 19, 22,
26].

The use of plant biotechnology to produce pharmaceutical and industrial
proteins has clear economic scalability and safety advantages as
compared to traditional microbial and mammalian production systems [9,
11, 12, 16, 17]. Plants offer potentially very high expression level of
recombinant proteins [10, 11]. However, the main advantage of plantbased expression systems is lack of harmful or even lethal contaminants
(viruses, toxins, prions, oncogenes) that might contaminate other
production systems [2, 9–12]. Current efforts are focused on maximizing
expression levels and accumulation of functional plant-produced proteins,
preferably in soluble form to facilitate purification [4, 5, 10, 11, 13, 23].
We previously expressed the GA733-2 antigen in planta using a tobacco
mosaic virus-based system. Although, mice immunized with the plantproduced product demonstrated an antigen-specific immune response,

small amounts of plant-derived material precluded complete
immunological assessment [26].
The use of modern transient and stable plant transformation systems
now allows the high yield production of GA733-2 TAA in plants. We found
that fusion to the endoplasmic reticulum (ER) retaining signal led to
increased levels of protein accumulation in plant cells, and an efficient
immuno-affinity purification procedure yielded EpCAM antigen (pGA733)
in sufficient amounts to confirm its protective immunogenicity in mice.
Antigen-specific serum antibodies from these mice inhibited tumor cell
growth in xenografted nude mice. Our results confirm the utility of plants
in high-yield and inexpensive production of drugs for cancer
immunotherapy.

Materials and methods

EpCAM expression cassette design

A DNA fragment of GA733-2 antigen extracellular domain (aa 24–264)
[20, 25] was amplified by the following primers: F-5′CCATGGCTCAGGAAGAATGTGTCTGT-3′ and R-5′GTCGACTTTATCATCATCATCAAGATCTTTTAG ACCCTGCATTGAGAATTCA3′, which carry NcoI and BglII sites, respectively. The product was
cloned into the pGEMT vector (Promega, Madison, WI, USA), sequenceverified, and recloned into plasmid pBIV-1.3Tag (Plant Research

International, Wageningen, NL, USA) comprised of the RbcS1 promoter,
C-terminal tags (c-myc and His6) and the KDEL retention ER signal. The
resulting expression cassette was transferred (AscI/PacI) into the plant
binary vector pBIN-Plus (Plant Research International), resulting in
plasmid pRB74, which was placed into Agrobacterium tumefaciens strain
LBA4404 for stable plant transformation. The GA733 NcoI/SacI fragment
from the pBIV-based construct was recloned into the carrier pro-vector
plasmid pICH11599 (Icon Genetics, Haale (Saale), Germany) and placed
in Agro-strain GV3101 for vacuum-infiltration “magnifection” of wild type
Swiss chard plants.

Transient and constitutive plant transformation

For rapid production of recombinant antigen, we used the magnifection
procedure [10, 11, 13, 18]. Agro-cultures carrying the expression
cassette were mixed with cultures carrying pre-manufactured helper
plasmids (pICH14011 and pICH17620) (Icon Genetics) and applied to
mature (6– 8 weeks old) Beta vulgaris var. cicla (Swiss chard) plants.
Plant tissues were harvested after 7–10 days and analyzed by Western
blot and ELISA. Low-alkaloid Nicotiana tabacum cv. LAMD609 (tobacco)
(Oxford Tobacco Research Station, Oxford, NC) was used for leaf explants
agro-mediated transformation [5] with pRB74. Independent transgenic
lines were selected in medium containing kanamycin (100 mg/l) and used

for molecular characterization.

Isolation and purification of plant (p) GA733 protein

Plant leaf tissues were collected and processed as described [5, 13]. After
centrifugation, supernatants were additionally successively clarified
through a Miracloth (Calbiochem, La Jolla, CA, USA) and a 0.45-µm filter
(Millipore, Bedford, MA, USA). Soluble protein extract was applied on a
murine mAb Ab733-immobilized HighTrap column (Amersham,
Piscataway, NJ, USA) or purified using His6 and c-myc tags as described
[13]. Eluates of recombinant pGA733 protein were combined, dialyzed
against PBS buffer and brought to a final concentration 1 mg/ml using
Amicon Ultra spin-column with a 10-kDa cut-off (Millipore). Aliquots were
frozen in liquid nitrogen and stored at 80°C. For analysis extracts were
¡

resolved by SDS-polyacrylamide gel electrophoresis (PAGE) and either
stained or transferred to a nitrocellulose membrane (Bio-rad, Hercules,
CA, USA), blocked with 5% non-fat milk and incubated with murine c-myc
mAb (Calbiochem, San Diego, CA, USA) or mAb Ab733 followed by
secondary anti-mouse Fc-specific Ab conjugated to horseradish
peroxidase (Sigma, St Louis, MO, USA) diluted 1:10,000. Reactive protein
bands were visualized using chemiluminescent substrate for peroxidase
(Pierce, Rockford, IL, USA).

Immunological analysis of pGA733 in mice

Eight-week-old female BALB/c mice (five per group) were injected with
three doses (5 µg) of pGA733 in a total volume of 100 µl at 2-week
intervals. First and second immunizations were given subcutaneously
(s.c.) with complete and incomplete Freund’s adjuvant (Difco, Detroit, MI,
USA), respectively; the third dose was administered inter-peritoneally
(i.p.) in saline. Control groups received 5 µg per injection of baculovirusproduced bGA733 (kindly provided by Dr William Wunner, Wistar
Institute, Philadelphia, PA, USA) or total soluble protein extract (TSP)
from non-transgenic wild-type plants. Blood samples were collected by
retro-orbital bleeding before experiment and 10 days after the second
immunization; 10 days after the third immunization, mice were sacrificed
and bled by cardiac puncture. Sera were analyzed by ELISA and Western
blotting. ELISA for bGA733 (1 µg/ml in PBS) was performed essentially as
described [23]. Antigen-specific antibodies were detected using goat antimouse IgG (BD Biosciences, San Jose, CA, USA), goat anti-mouse IgG2b
and IgG3 (Bethyl Labs, Montgomery, TX, USA) and rat anti-mouse IgG1
and IgG2a (BD Biosciences). Results are presented as mean ±SD.

Inhibition of tumor growth in vivo

Human colorectal carcinoma cells SW948 were maintained according to

the supplier’s instructions (ATCC) in DMEM supplemented with 10% FBS.
Six-to-8-week-old BALB/c nu/nu mice (5 per group) (Charles River
6

Laboratories, Wilmington, MA, USA) were inoculated s.c. with 10 cells on
the back of the neck followed immediately by four i.p. injections at 3-day
intervals with 100 µl of serum from pGA733 or bGA733 immunized
BALB/c mice for a total of 400 µl during 7 days. Control groups were
injected with 100 µl of TSP serum or 100 µg of mAb CO17-1A (Centocor,
Horsham, PA, USA) using the same regimen. Tumor growth was recorded
at 10, 15, 17, 19, 22, 24, 26, 29, 31, 35 and 38 days after initial injection
and calculated based on the three major diameters measured with
graduated calipers. At the end of the experiment, mice were euthanized
by CO2 inhalation in accordance with the institutional guidelines for animal
welfare.

Results

Production and puriWcation of pGA733 (EpCAM)

cDNA of the extracellular domain of antigen GA733 (aa 24–264) was
inserted into the pBIV-1.3Tag vector as a translational fusion with the ER
signal peptide; c-myc and His6 tag epitopes and the ER retention signal
KDEL (Plant Research International) were attached to the GA733 C-terminus. The antigen expression cassette containing promoter and

termination signal was placed in the pBINPlus binary vector, yielding the
construct pRB74 (Fig. 1a). EpCAM coding sequence (except ER signal
peptide) was subcloned into the magnICON Icon Genetics’ plasmid
pICH115999 (Fig. 1a) and used for transient expression of pGA733 [11,
13, 18].
The magnifection technique provided a robust and rapid way to express
recombinant pGA733 transiently in a large biomass plant, such as Swiss
chard (Fig. 1b, left). The recombinant protein was readily detected by
Western blotting at 7–9 days, post-infection in transfected leaf tissues
(Fig. 1b, right).
Several stably transformed transgenic tobacco lines selected based on
kanamycin resistance (Fig. 1c, left) showed detectable amounts of
pGA733 in leaf extracts on Western blot analysis (Fig. 1c, right).
Quantitative ELISA indicated a variable level of recombinant antigen
expression with up to 10 mg/kg of fresh leaves (not shown). The
transgenic line with the highest detectable antigen amount was selfcrossed to obtain a homozygous line.
The GA733 protein remained stable in fresh and lyophilized plant tissues
at ambient temperatures or at 4°C and was used to obtain standardized
samples at purity suitable for immunization (Fig. 1d). Plant-derived
antigen was purified from tobacco and Swiss chard plants by single step
antigen-specific immunoaffinity chromatography and/or by two-step

affinity tag-specific technique, yielding ~5 mg of pGA733 from 1 kg of
fresh leaf tissue as verified by SDSPAGE (Fig. 1d, left) and quantitative
ELISA. Equal amounts of plant and baculovirus produced GA733, as
determined by protein assay, produced bands of similar intensity on
coomassie gel and western blot and the same OD in quantitative ELISA
with monoclonal antibodies against GA733. Purified product resolved as a
double-band (both ~30 kDa) with a few additional minor bands confirmed
to be subproducts of pGA733 by immunostaining analysis (right). The
purity of plant-derived antigen as visualized on SDS-PAGE is ~60% (left).
Note that migration of the plant-derived protein was slower than that of
bGA733 (Fig. 1d), possibly reXecting the presence of the cmyc and His6
tags and the KDEL peptide.

Immune response of mice injected with pGA733

All mice injected with pGA733 or bGA733 antigen mounted a strong
GA733-speciWc serum antibody response, with comparable titers after
either immunization as tested in ELISA against plant- and baculovirusderived antigen (Fig. 2a). As expected, both IgG1 and IgG2a/b subclasses
were present in the sera, with slight predominance of IgG1 (Fig. 2b).
Western blotting confirmed the serum specificity of anti-GA733 antibodies
in mice immunized with bGA733 or pGA733 (Fig. 2c).
Suppression of tumor growth in mice by plant-derived vaccine

In nude mice xenografted with SW948 colorectal cancer cells and treated
with plant TSP serum, the first signs of tumor appeared 10 days after
3

injection; thereafter, tumors grew rapidly, averaging 1,357 mm by day
38 (Fig. 3). The first signs of tumor appeared by day 15 in mice treated
with pGA733 and bGA733 sera and by day 22 in mice treated with mAb
CO17-1A (Fig. 3a). In bGA733-treated group, all mice developed tumors,
although development was significantly delayed in two mice. In the mAb
CO17-1A treated group, two mice remained tumor-free for the 38-day
observation period. At 38 days, mean tumor volumes of both pGA733 and
bGA733-treated mice were significantly lower than that of the TSP control
group (P < 0.0001) (Fig. 3a, b). One mouse in pGA733 group remained
tumor free throughout the 38-day observation period. In control plant
TSP sera-treated group, all mice developed tumors (Fig. 3b, bottom).

Discussion

Several TAAs have been identified and their immune interactions in
patients have been well characterized. In numerous cases, immune
approaches to the treatment of cancer have entered the clinical stage [6,
21]. The EpCAM TAA, which has been studied for more than 20 years, is
one of the best-described candidates for active immunotherapy of
colorectal cancer [20].

In the last 2 decades, the use of plants for production of a range of
different therapeutics has been explored [9, 12, 16, 17]. Our recent
comparison of the immune response induced by GA733 produced in
baculovirus-infected insect cell culture versus GA733 produced in planta
using a viral vector [26] revealed a similar antibody response to both
antigens in mice, with similar tumor cell specificity in in vitro assay.
However, the low expression level in this prevented comparison of the
anti-cancer activity of the mouse in vivo.
In this study, we used modern plant production schemes [5, 13] to
efficiently express the EpCAM TAA. High-yield production was achieved
using the “ImpactVector system”, which is using the strong RbcS1
promoter from Chrysanthemum and allows direction of antigen expression
into specific plant cell compartments. Fusion of c-myc and His6 tags, as
well as the ER retention signals KDEL to the C-terminus of GA733
facilitated detection and purification of the antigen. Furthermore, using
this expression cassette, we produced considerable amounts of pGA733expressing leaf biomass using rapid and robust magnification of the
vegetable plant Swiss chard. Recombinant antigen was expressed at
levels of 5–10 mg/kg of fresh leaf material.
The recombinant pGA733 was readily extracted from the pooled leaf
material in soluble form. Transgenic T0 tobacco plants with the highest
expression level were processed in a one-step, immunoaffinity-based

purification procedure that resulted in ~50% recovery of recombinant
antigen from plant tissue (~5 mg/kg). Although transient expression and
double-step purification was even more efficient, stably transformed lowalkaloid tobacco appears to be more economically feasible.
The immune response to pGA733 appeared to be the same or only
slightly weaker than that of an equal dose of bGA733 in BALB/c mice. It
seems unlikely that differential reactivity, e.g., due to different
glycosylation patterns in pGA733 and bGA733, underlies this observation,
since similar results were obtained in ELISA with either antigen.
Moreover, Western blot analysis of mouse sera against pGA733 and
bGA733 at 1:10,000 dilutions revealed similar patterns, indicating high
purity of both antigens. Reactivity of anti-pGA733 sera appeared to be in
this case a bit higher with pGA733 compared to bGA733 (Fig. 2c). In
earlier analyses of the immunological properties of pGA733 using QS21 as
adjuvant, we observed a predominantly IgG1 response [26], whereas in
the present study we detected a higher percentage of IgG2a/b antibodies
in sera of mice immunized with either pGA733 or bGA733, although IgG1
antibodies remained a prominent subclass (Fig. 2b). This is likely due to
the use of Freund’s adjuvant.
Sera from mice immunized with pGA733, bGA733 or mAb CO17-1A
demonstrated significant inhibition of tumor growth in comparison to TSP
control sera in xenografted nude mice. There were no significant

differences between sera from mice immunized with pGA733 or bGA733
in tumor growth inhibition in vivo. The mAb CO17-1A sera had some
advantage over pGA733 and bGA733 sera during the early period (days
15–19) but the difference became insignificant later on (days 22–38) (Fig.
3a).
The possibility that pre-assembled antigen-antibody immune complexes
might have superior immunogenicity [3] awaits analysis using plantderived mAb CO17-1A [15] and plant-derived EpCAM antigen.
Our data clearly demonstrate that pGA733-generated sera display
comparable in vitro and in vivo activity to the sera generated against the
bGA733 antigen and can efficiently inhibit tumor growth in vivo. This work
points to the promise of transgenic plants as an excellent source of anticancer vaccines, particularly in the case of this attractive target—EpCAM
antigen, which is known to be immunogenic in humans [24].
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Figures

Fig. 1 Expression of EpCAM in plants.
a Colorectal cancer-associated antigen EpCAM/GA733-2 was assembled in
plant expression vectors pBIN-plus (ImpactVector) and pICH115999
(MagnICON) for stable and transient plant transformation, respectively.
The final expression cassette contains: the rubisco small subunit
promoter, RbcS1, driving the coding sequence of EpCAM antigen; the ER
signal peptide (SP) and retention signal KDEL; a cassette (nptII)
conferring resistance to the antibiotic kanamycin, and c-myc and H6 tags.

All components are located within the left (LB) and right (RB) borders of
TDNA (plasmid pRB74) for stable transformation.
b Six-week-old Swiss chard plants were used for MagnICON-based
expression (left). Soluble pGA733 was detected at 7, 8 and 9 days post
inoculation (dpi) by Western blotting with antigen-specific mAb in total
soluble protein (TSP) extracts (right).
c Stably transformed tobacco plants (left) and Western blotting (right) of
total protein extract from this plants probed with murine mAb AB733.
Positive control (+) is the bacteria-expressed GA733 antigen; protein
extract from non-transgenic wild-type (wt) tobacco served as a negative
control.
d SDS-PAGE and Western blotting (at 1:1000 dilution) of soluble pGA733
affinity-purified from plant leaf tissues compared with purified bGA733.
Numbers on the left indicate molecular size (kDa).

Fig. 2 Serum antibody response to EpCAM in BALB/c mice.
a ELISA titers of sera from BALB/c mice immunized with pGA733 or
bGA733 antigen. Results are presented as mean ±SD.
b ELISA IgG subclass titers of the pooled pGA733 and bGA733 sera in
panel a.
c Serial dilutions of pGA733 and bGA733 protein preparations (1:3)
probed with the corresponding pooled sera (1:10,000 dilution) obtained
after the third immunization of mice in panel A.

Fig. 3 Suppression of tumor growth in nude mice by pGA733-specific
antibodies.
6

a BALB/c nu/nu mice xenografted with 10 SW948 colorectal cancer cells
were injected with serum from BALB/c mice immunized with either
pGA733 or bGA733 antigen, or received serum from mock-immunized
(plant TSP) mice, or murine mAb CO17-1A. At days 2, 4 and 7, all mice
were injected with three additional doses of sera or antibodies. Tumor
3

volumes (mm ) were recorded at 10, 15, 17, 19, 22, 24, 26, 29, 31, 35

and 38 days after initial inoculation with cancer cells. Data are given as
mean ±SD.
b Pictures of mice treated with pGA733 sera (top) or control plant TSP
sera (bottom) were taken on day 35 after injection of tumor cells. Tumor
areas are circled; arrows indicate tumor cell injection sites.

